CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective faithfully but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my past several shares. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a very marketing picture in the Uptick Newswire job interview that I came away with a bad viewpoint of the business.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, though the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this expertise and linked intellectual property coming from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) plus the first new drug application approval ($five million), and also royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and numerous therapies, it’s this individual therapies in addition to a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

Its opening banner on its site (below) shows an active company with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple delivering presentations in addition to multiple publications.

Could it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the very beginning of my interest in this company. Judging by way of the multiples of a huge number of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or even some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News